SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 1

<210> SEQ ID NO 1
<211> LENGTH: 623
<212> TYPE: DNA
<213> ORGANISM: Epstein-Barr Virus

<400> SEQUENCE: 1

caagaattct catgtttgac agcttatcat cgtgaggata gcatatgcta cccggataca 60

gattaggata gcatatacta cccagatata gattaggata gcatatgcta cccagatata 120

gattaggata gcctatgcta cccagatata aattaggata gcatatacta cccagatata 180

gattaggata gcatatgcta cccagatata gattaggata gcctatgcta cccagatata 240

gattaggata gcatatgcta cccagatata gattaggata gcatatgcta tccagatatt 300

tgggtagtat atgctaccca gatataaatt aggatagcat atactaccct aatctctatt 360

aggatagcat atgctacccg gatacagatt aggatagcat atactaccca gatatagatt 420

aggatagcat atgctaccca gatatagatt aggatagcct atgctaccca gatataaatt 480

aggatagcat atactaccca gatatagatt aggatagcat atgctaccca gatatagatt 540

aggatagcct atgctaccca gatatagatt aggatagcat atgctatcca gatatttggg 600

tagtatatgc tacccatggc aac 623

1-50. (canceled)

51. An expression vector comprising a CMV5 promoter for driving expression of a recombinant protein and further comprising the nucleotide sequence set forth in SEQ ID NO: 1 or a fragment thereof comprising 9 to 20 EBNA1 binding sites,

wherein each of the EBNA1 binding sites is selected from the group consisting of nucleotides 36-53 of SEQ ID NO: 1, nucleotides 66-83 of SEQ ID NO: 1, nucleotides 126-143 of SEQ ID NO: 1, nucleotides 276-293 of SEQ ID NO: 1 and nucleotides 302-319 of SEQ ID NO: 1; and

the size of the expression vector is about 5925 base pairs or less.

52. The expression vector of claim **51**, wherein the size of the expression vector is from about 4185 base pairs to about 5925 base pairs.

53. The expression vector of claim **51**, wherein the fragment of SEQ ID NO: 1 consists of a BxtXI-EcoRI FR fragment consisting of nucleotides 5 to 299 of SEQ ID NO: 1.

54. The expression vector of claim **51**, wherein the fragment of SEQ ID NO: 2 consists of a BxtXI FR fragment consisting of nucleotides 300 to 595 of SEQ ID NO: 1.

55. The expression vector of claim **51**, further comprising an antibiotic resistance gene and a bacterial origin of replication, wherein the antibiotic resistance gene and the bacterial origin of replication are located between SEQ ID NO: 1 or the fragment thereof and the 5' end of the CMV5 promoter.

56. The expression vector of claim **55**, wherein the bacterial origin of replication is pMB1 and/or the antibiotic resistance gene is an ampicillin resistance gene.

57. The expression vector of claim **51**, further comprising a nucleotide sequence encoding a recombinant protein, wherein the nucleotide sequence encoding the recombinant protein is under control of the CMV5 promoter.

58. A process for preparing a recombinant protein, the process comprising transfecting human kidney cells of the 293 cell line with the expression vector of claim **57** and culturing the transfected cells to allow expression of the recombinant protein by the transfected cells.

59. The process of claim **58**, wherein the cells stably express EBNA1.

60. The process of claim **58**, wherein the cells are human kidney cells designated 293SFE and deposited under IDAC Accession No. 020502.

61. The process of claim **58**, wherein transfection of the cells is carried out in the presence of polyethylenimine (PEI) as a transfection reagent.

62. The process according to claim **61**, wherein the polyethylenimine is a linear polyethylenimine or a branched polyethylenimine.

63. The process according to claim **62**, wherein the average molecular weight of the polyethylenimine is from about 10 to about 100 kDa.

64. The process according to claim **62**, wherein the average molecular weight of the polyethylenimine is about 25 kDa.

65. The process according to claim **58**, wherein the cells are cultured in a serum-free culture medium.

66. The process according to claim **58**, wherein the cells are cultured in a culture medium comprising a serum or a subfraction thereof.

67. The process according to claim **58**, wherein the cells are cultured in a culture medium comprising a peptone.

68. The process according to claim **67**, wherein the peptone is the gelatin peptone N3.